BRPI0511569A - composições e métodos para o tratamento de distúrbio disfórico pré-menstrual - Google Patents

composições e métodos para o tratamento de distúrbio disfórico pré-menstrual

Info

Publication number
BRPI0511569A
BRPI0511569A BRPI0511569-8A BRPI0511569A BRPI0511569A BR PI0511569 A BRPI0511569 A BR PI0511569A BR PI0511569 A BRPI0511569 A BR PI0511569A BR PI0511569 A BRPI0511569 A BR PI0511569A
Authority
BR
Brazil
Prior art keywords
compositions
methods
treatment
dysphoric disorder
premenstrual dysphoric
Prior art date
Application number
BRPI0511569-8A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Karen Walsh
Diane Harrison
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0511569A publication Critical patent/BRPI0511569A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçõES E MéTODOS PARA O TRATAMENTO DE DISTúRBIO DISFóRICO PRé-MENSTRUAL. A presente invenção refere-se a um método para o tratamento de distúrbio disfórico pré-menstrual através de administração de pelo menos uma progestina e pelo menos um estrogênio a um indivíduo feminina por pelo menos (100) dias.
BRPI0511569-8A 2004-05-26 2005-05-09 composições e métodos para o tratamento de distúrbio disfórico pré-menstrual BRPI0511569A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57465104P 2004-05-26 2004-05-26
PCT/US2005/016180 WO2005117898A1 (en) 2004-05-26 2005-05-09 Compositions and methods for treatment of premenstrual dysphoric disorder

Publications (1)

Publication Number Publication Date
BRPI0511569A true BRPI0511569A (pt) 2008-01-02

Family

ID=34969878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511569-8A BRPI0511569A (pt) 2004-05-26 2005-05-09 composições e métodos para o tratamento de distúrbio disfórico pré-menstrual

Country Status (13)

Country Link
US (1) US20050272712A1 (pt)
EP (1) EP1755618A1 (pt)
JP (1) JP2008500340A (pt)
CN (1) CN1972692A (pt)
AR (1) AR049112A1 (pt)
AU (1) AU2005249401A1 (pt)
BR (1) BRPI0511569A (pt)
CA (1) CA2566811A1 (pt)
GT (1) GT200500127A (pt)
MX (1) MXPA06013418A (pt)
PE (1) PE20060275A1 (pt)
TW (1) TW200602063A (pt)
WO (1) WO2005117898A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
DE602004018921D1 (de) * 2003-06-25 2009-02-26 Bayer Schering Pharma Ag D dienogest

Also Published As

Publication number Publication date
WO2005117898A1 (en) 2005-12-15
AU2005249401A1 (en) 2005-12-15
CA2566811A1 (en) 2005-12-15
TW200602063A (en) 2006-01-16
MXPA06013418A (es) 2007-01-23
EP1755618A1 (en) 2007-02-28
PE20060275A1 (es) 2006-05-26
GT200500127A (es) 2006-03-23
JP2008500340A (ja) 2008-01-10
CN1972692A (zh) 2007-05-30
AR049112A1 (es) 2006-06-28
US20050272712A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
BRPI0508561A (pt) 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas
PL1613315T3 (pl) Pochodne chinolino-2-onu do leczenia chorób dróg oddechowych
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
EP2177224A3 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
ECSP099695A (es) Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos
BR112018070946A2 (pt) administração de um construto biespecífico que se liga a cd33 e cd3 para uso em um método para o tratamento de leucemia mieloide
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
WO2019224790A3 (en) Prodrugs of fulvestrant
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BR0208052A (pt) Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas
BRPI0512841A (pt) composições e métodos para o tratamento de infecções patológicas
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
BRPI0506493A (pt) combinações terapêuticas
BRPI0509653A (pt) inibidores cinesina mitótica
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.